PHARMA SECTOR
Sensex & Nifty fall in Muhurat trade for first time since 2017
Indian equities experienced a slight decline during the Diwali Muhurat trading session for the first time since 2017. The Sensex ended at 80,999.40, down 28.62 points, and the Nifty closed at 24,986.40, shedding 43.95 points. Despite the drop, market sentiment has recently shown signs of improvement, particularly with foreign investors becoming buyers again.
Ahead of Market: 10 things that will decide stock market action on Monday
Sensex and Nifty ended lower during Muhurat Trading on November 8, snapping a six-session winning streak. Nifty slipped below 25,000 as investors booked profits. However, broader market sentiment remained positive, with 2,716 NSE stocks advancing against 736 declines.
PSBs, pharma and defence: HDFC Securities CEO names Samvat 2083’s dark horses
HDFC Securities MD and CEO Dhiraj Relli identifies public sector banks, pharmaceuticals and defence as potential outperformers in Samvat 2083. He favours largecaps for valuation comfort, highlights selective stock opportunities and urges investors to prioritise earnings visibility and disciplined asset allocation.
Dalal Street Week Ahead: Nifty bulls come back to life, but 25,000–25,200 zone poses next test
Indian equity markets rallied significantly following the results of the US midterm elections, which were favorable for investors. The Nifty Index saw a large gain and reclaimed important moving averages, indicating improved market sentiment. Some consolidation is expected, as the Index approaches broader resistance levels between 25,000 and 25,200. Various sector indices showed differing momentum as they contrasted against the broader Nifty 500 Index.
Samir Arora backed Helios Mid Cap Fund adds Aurobindo Pharma, 2 others, increase stake in Paytm, MCX and 16 others
Samir Arora-backed Helios Mid Cap Fund added Aurobindo Pharma, Zetwerk and PVR Inox in October, while increasing stakes in Paytm, MCX and 16 other stocks. The fund exited Park Medi World, expanded its portfolio to 77 stocks and reported assets under management of Rs 2,421 crore.
Market wrap: Bajaj Finance, Shriram Finance, Apollo Hospital, ONGC top gainers and losers on Nifty and Sensex on Thursday
Indian equity markets staged a strong rally on Thursday, with the Sensex surging over 2,000 points and the Nifty jumping 576 points amid optimism following the US midterm election results. Bajaj Finance, Shriram Finance and M&M led the gainers, while Apollo Hospitals and ONGC featured among the top laggards.
Pills are paying off! Pharma stocks lead 2026 rally with up to 112% return
In 2026, India's pharmaceutical stocks are making headlines with impressive year-to-date gains. This surge is driven by strong domestic demand alongside enhanced profitability from new product launches. Notable players like Laurus Labs and Gland Pharma have recorded remarkable returns, topping 100%. Amid challenges faced by other sectors, the pharmaceutical field demonstrates resilience. Analysts are optimistic but advise exercising caution regarding potential market volatility and the durability of this sector's performance.
Global Market Today: Asian stocks rise as oil slides after US midterm elections
Benchmark indexes rose in Japan and Australia, pushing the MSCI Asia Pacific Index up by 0.3%. That was after the S&P 500 Index jumped 1.6%, its biggest gain in three months, and the tech-heavy Nasdaq 100 climbed 0.9%. South Korea was the outlier, with the Kospi Index dropping 2.7%, reflecting investor concerns over the future of data-center development and losses in US chip stocks.
Stocks in news: BSE, Lenskart, Nykaa, Bharti Airtel, LIC, Aurobindo Pharma and Nalco
Indian equity markets have enjoyed a remarkable stretch, registering gains for five consecutive sessions. The Nifty 50 index showed impressive growth, sparking optimism for a breakout beyond 24,000. Companies like Lenskart, Aurobindo Pharma, and BSE are in the spotlight as they report positive earnings. Experts advise keeping an eye on the support levels as the bullish trend persists.
Emcure Pharma shares hit 10% upper circuit after FY27 guidance hike; Jefferies raises target price by 8%
Emcure Pharma shares hit a 10% upper circuit after strong Q2 FY27 results prompted the company to raise its full-year growth guidance. Brokerages turned more positive, citing robust international business, improving domestic growth and a strong product pipeline.
India has never allowed genetically modified products' import, won't do in future: Piyush Goyal
India continues to maintain a strict policy against the import of genetically modified products, as stated by Minister Piyush Goyal. He highlighted that the dairy sector remains particularly sensitive and has not been opened in trade agreements. Goyal emphasized India's commitment to protecting its agricultural and fisheries sectors while seeking preferential market access for textiles and pharmaceuticals.
Bonus issue alert! Last day to buy this Rakesh Jhunjhunwala-backed smallcap pharma stock for 1:1 bonus bonanza
As per Sebi's T+1 settlement cycle, investors must buy the company's shares at least one trading day before the record date for them to be credited to their demat accounts and qualify for the bonus issue. This makes today the last day to buy the stock to be eligible for the bonus shares.
Market wrap: RIL, Tata Steel, Infosys, ICICI Bank top gainers and losers on Nifty and Sensex on Monday
Indian markets rallied sharply, with Sensex gaining 1.66% to 75,693 and Nifty rising 1.68% to 23,441. Strong quarterly earnings lifted investor sentiment, led by Reliance Industries, metals and oil and gas stocks, while market breadth remained positive.
Diwali investment picks 2026: 10 fund managers reveal promising opportunities and risks to watch
This Diwali, investment experts advise a strategic approach focused on asset allocation rather than luring high-growth stocks. Sectors like banking, financial services, and premium goods present promising opportunities. While gold should only occupy a small fraction of a diversified portfolio for risk management, short-duration debt funds gain favour as interest rates shift. Maintaining discipline and patience is essential for long-term investment success.
Diwali 2026: 77 stocks knock down D-St bears to deliver multibagger returns of up to 4,700% in a year
With Diwali 2026 on the horizon, 77 stocks have thrived despite market fluctuations, marking exceptional returns. Mrugesh Trading showcases an astonishing gain of 4,657%, while Axis Solution follows closely with 1,081%. Other strong performers are Sterlite Technologies and Cupid, each demonstrating impressive growth. Analysts are hopeful for a market rebound thanks to falling crude oil prices, which could positively impact sectors such as automotive, capital goods, and pharmaceuticals.
India’s medicine sales grow in double digits for four straight quarters, led by chronic care drugs
Over the past four quarters, India's medicine sales have increased significantly due to rising demand in chronic care segments. The growth rate reached 12% year-on-year in the September quarter, showing a positive trend in the industry. Larger pharmaceutical companies have benefited from the shutdown of many non-compliant smaller units. Budgets were also boosted by a reduction in GST on medicines.
Short-term headwinds, yes; owning the ecosystem is better: 20 healthcare stocks with downside risk of 23% to upside potential of 41%
The healthcare sector is under scrutiny. The issue is pricing: What medicines cost and on what hospitals and the rest of the health ecosystem charge. And both the government and the courts have stepped in. At one level, that is not entirely a bad thing. Check out Stock Reports Plus, powered by Refinitiv, for price targets of over 4,000 listed stocks along with detailed company analysis focusing on five key components – earnings, fundamentals, relative valuation, risk, and price momentum – to generate standardised scores. SR+ Reports is a complimentary offering to ETPrime members.
Sensex rises 308 points, Nifty above 23,000 even as broader markets crash. Will D-Street bulls extend recovery next week?
Indian market indices Sensex and Nifty ended the week on a high note, each climbing by up to 0.5%. Even as the broader market suffered losses, standout performers like Trent and IndiGo flourished thanks to positive earnings. The Nifty IT index was a highlight, soaring over 2%, while Nifty Consumer Durables fell nearly 2%.
Mankind Pharma shares jump 8% as Q2 profit rises 38% to Rs 716 crore
Mankind Pharma shares jumped nearly 8% after the company reported a 38% year-on-year rise in Q2 profit to Rs 716 crore. Revenue grew 17%, supported by domestic and export growth, while EBITDA margins expanded 210 basis points.
Load More
